181. Front Oncol. 2018 Apr 4;8:84. doi: 10.3389/fonc.2018.00084. eCollection 2018.Management of the Axilla in the Era of Breast Cancer Heterogeneity.de Meric de Bellefon M(1), Lemanski C(1), Ducteil A(1), Fenoglietto P(1), AzriaD(1)(2)(3), Bourgier C(1)(2)(3).Author information: (1)Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.(2)Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194,Montpellier, France.(3)Université de Montpellier, Montpellier, France.Systemic cancer therapies take into account breast cancer (BC) heterogeneity bytargeting pathways specifically involved in some BC subtypes. On the other hand, BC intrinsic radiosensitivity is poorly understood and studied. Hence,radiotherapy personalization in BC is still "work in progress". In this review,we will summarize the existing data on the management of axillary lymph nodes in BC, the impact of BC radiotherapy on axillary management, the indications foraxillary radiotherapy, and biomarkers to predict patients' outcome (tumor controland late toxicities) after axillary irradiation.DOI: 10.3389/fonc.2018.00084 PMCID: PMC5893721PMID: 29670853 